Trial Profile

A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, With Open Label Extension, in Patients With Treatment-Resistant Depression

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
Indications Major depressive disorder; Treatment-resistant depressive disorder
Focus Therapeutic Use
Sponsors Beckley Psytech

Most Recent Events

16 Jan 2026 Results presented in the Atai Beckley Media Release
16 Jan 2026 According to Atai Beckley media release, data from the trial were presented in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), which took place on January 12 - 15, 2026 in Nassau, The Bahamas.
10 Nov 2025 Topline results presented in the AtaiBeckley media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com